Revenue: As of FY2026 Q1, the actual value is USD 240 K.EPS: As of FY2026 Q1, the actual value is USD -0.19.EBIT: As of FY2026 Q1, the actual value is USD -10.38 M.<h3>Healthcare Segment</h3><ul><li>Product Revenue: $154,000 for the three months ended October 31, 2025, compared to $0 for the same period in 2024, primarily due to the inclusion of product revenue generated by Cyclo following the Cyclo Merger in March 2025.</li><li>Cost of Product Revenue: $9,000 for the three months ended October 31, 2025.</li><li>General and Administrative Expenses: Increased to $2,752,000 for the three months ended October 31, 2025, from $2,290,000 in the same period in 2024, primarily due to the consolidation of Cyclo’s expenses.</li><li>Research and Development Expenses: Increased to $7,484,000 for the three months ended October 31, 2025, from $1,161,000 in the same period in 2024, mainly due to Cyclo’s expenses.</li><li>Loss from Operations: - $10,124,000 for the three months ended October 31, 2025, compared to - $3,522,000 for the same period in 2024.</li></ul><h3>Infusion Technology Segment</h3><ul><li>Revenue: $0 for the three months ended October 31, 2025, compared to $51,000 for the same period in 2024, due to the sale of certain assets and licensing of technology.</li><li>Cost of Revenue: $0 for the three months ended October 31, 2025, compared to $37,000 for the same period in 2024.</li><li>General and Administrative Expenses: Decreased to $29,000 for the three months ended October 31, 2025, from $112,000 in the same period in 2024.</li><li>Research and Development Expenses: $0 for the three months ended October 31, 2025, compared to $165,000 for the same period in 2024.</li><li>Loss from Operations: - $29,000 for the three months ended October 31, 2025, compared to - $263,000 for the same period in 2024.</li></ul><h3>Real Estate Segment</h3><ul><li>Rental Revenue: $56,000 from third parties and $30,000 from related parties for the three months ended October 31, 2025, compared to $50,000 and $27,000, respectively, for the same period in 2024.</li><li>General and Administrative Expenses: Decreased to $57,000 for the three months ended October 31, 2025, from $121,000 in the same period in 2024.</li><li>Income (Loss) from Operations: $12,000 for the three months ended October 31, 2025, compared to - $59,000 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Rafael Holdings, Inc. aims to complete the development of Trappsol® Cyclo™ through its ongoing pivotal Phase 3 clinical trial and bring the product to regulatory approval and market. The company is also focused on expanding its investment portfolio through strategic investments in therapeutics addressing high unmet medical needs.</li><li>Non-Core Business: The company is evaluating its other holdings to ensure future focus on core assets, specifically the Trappsol® Cyclo™ clinical and development efforts.</li></ul>

Rafael-B | 10-Q: FY2026 Q1 Revenue: USD 240 K